VERAXA Biotech AG (NASDAQ: VRXA) has announced a significant expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 that cover its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company also noted that previously granted patents protecting supporting technologies have cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. With pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. This approach aims to reduce off-target effects and enhance therapeutic efficacy. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to improve the safety, efficacy and manufacturability of its antibody-drug conjugate (ADC) and T-cell engager pipelines. These advancements reinforce the company's long-term strategy to develop next-generation oncology therapeutics.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
For more information, visit the company’s newsroom at http://ibn.fm/VRXA. The full press release is available at https://ibn.fm/BqhFS.
